A positive or negative change of PD-L1 could not be associated with response to neoadjuvant therapy (major pathological response [MPR] yes/no), patients’ sex, tumor histology or change of CD8 + TILs density (Supplementary table 3). This evidence concerns the gene CD8A and neoplasm.